SOD1 plasma level as a biomarker for therapeutic failure in cutaneous leishmaniasis

Journal of Infectious Diseases

Volumn 210, Issue 2, 2014, Pages 306-310

  Khouri, Ricardo ^a,b,d   Santos, Gilvaneia Silva ^a   Soares, George ^a   Costa, Jackson M ^a   Barral, Aldina ^a,b,c   Barral Netto, Manoel ^a,b,c   Van Weyenbergh, Johan ^a,d  

^a INSTITUTO OSWALDO CRUZ   (Brazil)

^b FEDERAL UNIVERSITY OF BAHIA   (Brazil)

^c Institute of Investigation in Immunology iii   (Brazil)

^d REGA INSTITUTE FOR MEDICAL RESEARCH   (Belgium)

Author keywords

Biomarker

Indexed keywords

ALPHA INTERFERON; ANTIMONY; BETA INTERFERON; BIOLOGICAL MARKER; COPPER ZINC SUPEROXIDE DISMUTASE; MANGANESE SUPEROXIDE DISMUTASE; MEGLUMINE ANTIMONATE; MESSENGER RNA;

ADULT; ARTICLE; CONTROLLED STUDY; DRUG TREATMENT FAILURE; ENZYME ACTIVITY; ENZYME BLOOD LEVEL; FEMALE; HUMAN; LEISHMANIA BRAZILIENSIS; MACROPHAGE; MALE; NONHUMAN; PARASITE LOAD; PHENOTYPE; PRIORITY JOURNAL; PROTEIN FUNCTION; RECEIVER OPERATING CHARACTERISTIC; SENSITIVITY AND SPECIFICITY; SKIN LEISHMANIASIS; TREATMENT DURATION;

BIOMARKER; CUTANEOUS LEISHMANIASIS; DIFFUSE CUTANEOUS LEISHMANIASIS; INTERKINGDOM SIGNALING; LEISHMANIA AMAZONENSIS; LEISHMANIA BRAZILIENSIS; OXIDATIVE BURST; PARASITE ESCAPE MECHANISM; SUPEROXIDE DISMUTASE; THERAPEUTIC FAILURE;

ADULT; ANTIMONY; ANTIPROTOZOAL AGENTS; BIOLOGICAL MARKERS; CELLS, CULTURED; FEMALE; GENE EXPRESSION PROFILING; HUMANS; LEISHMANIA BRAZILIENSIS; LEISHMANIASIS, CUTANEOUS; MALE; SUPEROXIDE DISMUTASE; TREATMENT FAILURE;

EID: 84904012465     PISSN: 00221899     EISSN: 15376613     Source Type: Journal    
DOI: 10.1093/infdis/jiu087     Document Type: Article

References (15)

1. Desjeux P. Leishmaniasis: Current situation and new perspectives. Comp Immunol Microbiol Infect Dis 2004; 27:305-18. (Pubitemid 38842803)
2. Murray HW, Berman JD, Davies CR, Saravia NG. Advances in leishmaniasis. Lancet 2005; 366:1561-77. (Pubitemid 41540115)
3. Reithinger R, Dujardin JC, Louzir H, Pirmez C, Alexander B, Brooker S. Cutaneous Leishmaniasis. Lancet Infect Dis 2007; 7:581-96. (Pubitemid 47277438)
4. Modabber F, Buffet PA, Torreele E, Milon G, Croft SL. Consultative meeting to develop a strategy for treatment of cutaneous leishmaniasis. Kinetoplastid Biol Dis 2007; 6:3.
5. Llanos-Cuentas A, Tulliano G, Araujo-Castillo R, et al. Clinical and parasite species risk factors for pentavalent antimonial treatment failure in cutaneous leishmaniasis in Peru. Clin Infect Dis 2008; 46: 223-31. (Pubitemid 351269161)
6. Zerpa O, Ulrich M, Blanco B, et al. Diffuse cutaneous leishmaniasis responds to miltefosine but then relapses. Br J Dermatol 2007; 156:1328-35. (Pubitemid 47029811)
7. Plewes KA, Barr SD, Gedamu L. Iron superoxide dismutases targeted to the glycosomes of Leishmania chagasi are important for survival. Infect Immun 2003; 71:5910-20. (Pubitemid 37205644)
8. Ghosh S, Goswami S, Adhya S. Role of superoxide dismutase in survival of Leishmania within the macrophage. Biochem J 2003; 369:447.
9. Khouri R, Bafica A, Pereira Silva MP, et al. IFN-? impairs superoxidedependent parasite killing in human macrophages: evidence for a deleterious role of SOD1 in cutaneous leishmaniasis. J Immunol 2009; 182:2525-31.
10. Kocyigit A, Gurel M, Ulukanligil M. Erythrocyte antioxidative enzyme activities and lipid peroxidation levels in patients with cutaneous leishmaniasis. Parasite 2003; 10:277-81. (Pubitemid 37260066)
11. Soares G, Barral A, Costa JM, Barral-Netto M, Van Weyenbergh J. CD16+ monocytes in human cutaneous leishmaniasis: increased ex vivo levels and correlation with clinical data. J Leukoc Biol 2006; 79:36-9. (Pubitemid 43054247)
12. Geiss GK, Bumgarner RE, Birditt B, et al. Direct multiplexed measurement of gene expression with color-coded probe pairs. Nat Biotechnol. 2008; 26:317-25. (Pubitemid 351355126)
13. Barral A, Costa JM, Bittencourt AL, Barral-Netto M, Carvalho EM. Polar and subpolar diffuse cutaneous leishmaniasis in Brazil: clinical and immunopathologic aspects. Int J Dermatol 1995; 34:474-9.
14. Vivarini Ade C, Pereira Rde M, Teixeira KL, et al. Human cutaneous leishmaniasis: interferon-dependent expression of double-stranded RNA-dependent protein kinase (PKR) via TLR2. FASEB J 2011; 25:4162-73.
15. Khouri R, Novais F, Santana G, et al. DETC induces Leishmania parasite killing in human in vitro and murine in vivo models: a promising therapeutic alternative in Leishmaniasis. PLoS One 2010; 5: e14394.